FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916483558> ?p ?o ?g. }

• W2916483558 endingPage "5804" @default.
• W2916483558 startingPage "5790" @default.
• W2916483558 abstract "T-cell receptors (TCR) have considerable potential as therapeutics and antibody-like reagents to monitor disease progression and vaccine efficacy. Whereas antibodies recognize only secreted and surface-bound proteins, TCRs recognize otherwise inaccessible disease-associated intracellular proteins when they are presented as processed peptides bound to major histocompatibility complexes (pMHC). TCRs have been primarily explored for cancer therapy applications but could also target infectious diseases such as cytomegalovirus (CMV). However, TCRs are more difficult to express and engineer than antibodies, and advanced methods are needed to enable their widespread use. Here, we engineered the human CMV–specific TCR RA14 for high-affinity and robust soluble expression. To achieve this, we adapted our previously reported mammalian display system to present TCR extracellular domains and used this to screen CDR3 libraries for clones with increased pMHC affinity. After three rounds of selection, characterized clones retained peptide specificity and activation when expressed on the surface of human Jurkat T cells. We obtained high yields of soluble, monomeric protein by fusing the TCR extracellular domains to antibody hinge and Fc constant regions, adding a stabilizing disulfide bond between the constant domains and disrupting predicted glycosylation sites. One variant exhibited 50 nm affinity for its cognate pMHC, as measured by surface plasmon resonance, and specifically stained cells presenting this pMHC. Our work has identified a human TCR with high affinity for the immunodominant CMV peptide and offers a new strategy to rapidly engineer soluble TCRs for biomedical applications. T-cell receptors (TCR) have considerable potential as therapeutics and antibody-like reagents to monitor disease progression and vaccine efficacy. Whereas antibodies recognize only secreted and surface-bound proteins, TCRs recognize otherwise inaccessible disease-associated intracellular proteins when they are presented as processed peptides bound to major histocompatibility complexes (pMHC). TCRs have been primarily explored for cancer therapy applications but could also target infectious diseases such as cytomegalovirus (CMV). However, TCRs are more difficult to express and engineer than antibodies, and advanced methods are needed to enable their widespread use. Here, we engineered the human CMV–specific TCR RA14 for high-affinity and robust soluble expression. To achieve this, we adapted our previously reported mammalian display system to present TCR extracellular domains and used this to screen CDR3 libraries for clones with increased pMHC affinity. After three rounds of selection, characterized clones retained peptide specificity and activation when expressed on the surface of human Jurkat T cells. We obtained high yields of soluble, monomeric protein by fusing the TCR extracellular domains to antibody hinge and Fc constant regions, adding a stabilizing disulfide bond between the constant domains and disrupting predicted glycosylation sites. One variant exhibited 50 nm affinity for its cognate pMHC, as measured by surface plasmon resonance, and specifically stained cells presenting this pMHC. Our work has identified a human TCR with high affinity for the immunodominant CMV peptide and offers a new strategy to rapidly engineer soluble TCRs for biomedical applications. Weaponizing T-cell receptors through molecular engineeringJournal of Biological ChemistryVol. 294Issue 15PreviewT-cell receptors (TCRs) recognize pathogens to ignite immune responses, making them attractive scaffolds for development as immunotherapeutics. However, manipulation of TCRs has been impeded by difficulties in their engineering and expression. Wagner and colleagues now establish new platforms to generate high-affinity TCR variants that potently activate T cells, and they also create soluble TCR fusion proteins that specifically recognize cognate peptides. This work provides specific tools to combat cytomegalovirus (CMV) infection and helps illuminate a general path to actuation of engineered TCR-based therapeutics. Full-Text PDF Open Access" @default.
• W2916483558 created "2019-03-02" @default.
• W2916483558 creator A5013595637 @default.
• W2916483558 creator A5027065009 @default.
• W2916483558 creator A5043183449 @default.
• W2916483558 creator A5046526368 @default.
• W2916483558 creator A5079143219 @default.
• W2916483558 creator A5053102626 @default.
• W2916483558 date "2019-04-01" @default.
• W2916483558 modified "2023-09-26" @default.
• W2916483558 title "Human cytomegalovirus-specific T-cell receptor engineered for high affinity and soluble expression using mammalian cell display" @default.
• W2916483558 cites W1498780407 @default.
• W2916483558 cites W1499835878 @default.
• W2916483558 cites W1502917753 @default.
• W2916483558 cites W1589818703 @default.
• W2916483558 cites W1614704642 @default.
• W2916483558 cites W1865427247 @default.
• W2916483558 cites W1895052014 @default.
• W2916483558 cites W1908675203 @default.
• W2916483558 cites W1976058260 @default.
• W2916483558 cites W1977928371 @default.
• W2916483558 cites W1981964848 @default.
• W2916483558 cites W1982494709 @default.
• W2916483558 cites W1992253391 @default.
• W2916483558 cites W1995264543 @default.
• W2916483558 cites W1996626942 @default.
• W2916483558 cites W1998048927 @default.
• W2916483558 cites W2005274005 @default.
• W2916483558 cites W2007354859 @default.
• W2916483558 cites W2008284182 @default.
• W2916483558 cites W2014275356 @default.
• W2916483558 cites W2017173491 @default.
• W2916483558 cites W2019060451 @default.
• W2916483558 cites W2019421915 @default.
• W2916483558 cites W2022046221 @default.
• W2916483558 cites W2039206013 @default.
• W2916483558 cites W2041879875 @default.
• W2916483558 cites W2051715763 @default.
• W2916483558 cites W2068872497 @default.
• W2916483558 cites W2077200917 @default.
• W2916483558 cites W2077415084 @default.
• W2916483558 cites W2078607441 @default.
• W2916483558 cites W2086410416 @default.
• W2916483558 cites W2091567124 @default.
• W2916483558 cites W2093966230 @default.
• W2916483558 cites W2106582884 @default.
• W2916483558 cites W2108217273 @default.
• W2916483558 cites W2116117984 @default.
• W2916483558 cites W2118319010 @default.
• W2916483558 cites W2120518061 @default.
• W2916483558 cites W2122508875 @default.
• W2916483558 cites W2122837633 @default.
• W2916483558 cites W2124210101 @default.
• W2916483558 cites W2124985346 @default.
• W2916483558 cites W2132713837 @default.
• W2916483558 cites W2136673346 @default.
• W2916483558 cites W2138859976 @default.
• W2916483558 cites W2158777708 @default.
• W2916483558 cites W2159305020 @default.
• W2916483558 cites W2167420348 @default.
• W2916483558 cites W2167642721 @default.
• W2916483558 cites W2171373682 @default.
• W2916483558 cites W2186662694 @default.
• W2916483558 cites W2209422840 @default.
• W2916483558 cites W2217081146 @default.
• W2916483558 cites W2268663278 @default.
• W2916483558 cites W2432068972 @default.
• W2916483558 cites W2793406985 @default.
• W2916483558 cites W2805713983 @default.
• W2916483558 cites W2884809460 @default.
• W2916483558 cites W4313377012 @default.
• W2916483558 doi "https://doi.org/10.1074/jbc.ra118.007187" @default.
• W2916483558 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6463697" @default.
• W2916483558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30796163" @default.
• W2916483558 hasPublicationYear "2019" @default.
• W2916483558 type Work @default.
• W2916483558 sameAs 2916483558 @default.
• W2916483558 citedByCount "19" @default.
• W2916483558 countsByYear W29164835582019 @default.
• W2916483558 countsByYear W29164835582020 @default.
• W2916483558 countsByYear W29164835582021 @default.
• W2916483558 countsByYear W29164835582022 @default.
• W2916483558 crossrefType "journal-article" @default.
• W2916483558 hasAuthorship W2916483558A5013595637 @default.
• W2916483558 hasAuthorship W2916483558A5027065009 @default.
• W2916483558 hasAuthorship W2916483558A5043183449 @default.
• W2916483558 hasAuthorship W2916483558A5046526368 @default.
• W2916483558 hasAuthorship W2916483558A5053102626 @default.
• W2916483558 hasAuthorship W2916483558A5079143219 @default.
• W2916483558 hasBestOaLocation W29164835581 @default.
• W2916483558 hasConcept C147483822 @default.
• W2916483558 hasConcept C147816474 @default.
• W2916483558 hasConcept C153911025 @default.
• W2916483558 hasConcept C159654299 @default.
• W2916483558 hasConcept C170493617 @default.
• W2916483558 hasConcept C179464577 @default.
• W2916483558 hasConcept C181199279 @default.
• W2916483558 hasConcept C19317047 @default.

• next